.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Express Scripts
Accenture
Baxter
McKesson
Teva
AstraZeneca
Moodys
Citi
Cerilliant

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,241,946

« Back to Dashboard

Which drugs does patent 9,241,946 protect, and when does it expire?


Patent 9,241,946 protects ORACEA and is included in one NDA. There has been one Paragraph IV challenge on Oracea.

This patent has seventeen patent family members in twelve countries.

Summary for Patent: 9,241,946

Title:Methods of treating acne
Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.
Inventor(s): Ashley; Robert A. (Newtown, PA)
Assignee: GALDERMA LABORATORIES INC. (Fort Worth, TX)
Application Number:14/753,544
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs LpORACEAdoxycyclineCAPSULE;ORAL050805-001May 26, 2006RXYesYes► Subscribe► SubscribeTREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,241,946

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,014,858Use methods of treating acne and telangiectasia► Subscribe
8,658,189Methods of treating acne► Subscribe
8,052,983Methods of treating acne► Subscribe
8,603,506Methods of treating acne► Subscribe
7,232,572Methods of treating rosacea► Subscribe
7,211,267Methods of treating acne► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,241,946

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1383508► Subscribe
New Zealand528197► Subscribe
South Korea100926326► Subscribe
South Korea20040007488► Subscribe
Japan2011168613► Subscribe
Japan2010053155► Subscribe
Japan2004536046► Subscribe
Spain2266499► Subscribe
European Patent Office2221056► Subscribe
European Patent Office1716856► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Queensland Health
UBS
Novartis
Covington
Chubb
Baxter
US Department of Justice
Teva
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot